Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

56.050
+2.5504.77%
Volume:43.68M
Turnover:2.43B
Market Cap:230.70B
PE:41.30
High:56.500
Open:53.500
Low:53.250
Close:53.500
52wk High:56.500
52wk Low:28.480
Shares:4.12B
HK Float Shares:4.12B
Volume Ratio:2.19
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.357
ROE:11.38%
ROA:7.60%
PB:4.10
PE(LYR):41.30
PS:8.35

Loading ...

Wuxi Biologics (Cayman) Stock Rises 4.8% in Hong Kong

Dow Jones
·
Yesterday

Goldman Sachs: Asian CDMOs Enter a Structural Growth Cycle, with Peptides, ADCs, Oligonucleotides, and AIDD as New Engines

Stock News
·
Yesterday

Movement Alert|WUXI BIO Rises 3.27% in Regular Trading, Broker Upgrades and Policy Tailwinds Fuel CXO Rally

Market Focus
·
Yesterday

Southbound Trading Update: Net Buy of HKD 15 Million, Increased AIA (01299) Stake by Over HKD 800 Million, Sold Off Alibaba (09988) Over HKD 500 Million

Stock News
·
Sep 29

Movement Alert|WUXI BIO Rises 3.28% in Regular Trading, CXO Sector Boosted by Strong Earnings and Policy Tailwinds

Market Focus
·
Sep 29

HK Movers | Biotech Concept Stocks Buck Market Trend with Broad Gains; GENSCRIPT BIO Jumps Over 9%

Tiger Newspress
·
Sep 25

Hong Kong Stock Market Movers: CRO Sector Leads Gains as Citi Signals Positive Outlook for U.S. Licensing Policy Toward Chinese Drugmakers, Remains Bullish on Innovative Drugs and Biotech

Stock News
·
Sep 25

WuXi Biologics - Wuxi Mashan Site Passes Two-Week FDA Gmp Inspection

THOMSON REUTERS
·
Sep 24

Wuxi Biologics (Cayman) Stock Slips 1.7% in Hong Kong

Dow Jones
·
Sep 24

Wuxi Biologics Posts 18% Top-Line Growth and Strong Margin Expansion in 1H26, Bolstered by Backlog Surge and BioDlink Acquisition

Bulletin Express
·
Sep 22

Wuxi Biologics (Cayman) Stock Climbs 5.3% in Hong Kong

Dow Jones
·
Sep 21

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

Movement Alert|WUXI BIO Rises 3.28% in Regular Trading, Cancellation of Nearly 40 Million Repurchased Shares Boosts Per-Share Value

Market Focus
·
Sep 21

WUXI BIO Cancels 39.82 Million Treasury Shares Purchased Under Buyback Program

Deep News
·
Sep 21

Movement Alert|WUXI BIO Rises 3.09% in Regular Trading, CXO Sector Rallies as Global Pharma Outsourcing Rate Breaks 50%

Market Focus
·
Sep 18

WUXI BIO: Zhisheng Chen Disposes, Long Position Falls to 1.47%

HK Disclosure
·
Sep 17

WuXi XDC Out-Licenses WuXiTecan-2 ADC Payload-Linker Platform to Ona Therapeutics

Reuters
·
Sep 17

Wuxi Biologics (Cayman) Stock Advances 1.5% in Hong Kong

Dow Jones
·
Sep 16

WuXi Biologics Makes Forbes China ESG 50 List for 2026

Reuters
·
Sep 16

Movement Alert|WUXI BIO Rises 3.21% in Regular Trading, CXO Sector Extends Mid-Year Earnings Rally

Market Focus
·
Sep 16